OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
8
Results
Show all
Save search
Copy query
Show results for
Unknown
(8)
Publication Date
Release Date
2025
(3)
2022
(2)
2021
(2)
2023
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Extreme thrombocytosis with severe anemia and infection in a Sudanese patient: A case report.
Not available
S-EPMC9793150
|
biostudies-literature
Cite
Surveillance of antimicrobial resistance in the United Arab Emirates: the early implementation phase.
Not available
S-EPMC10704098
|
biostudies-literature
Cite
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Not available
S-EPMC7727327
|
biostudies-literature
Cite
The ChoCO-W prospective observational global study: Does COVID-19 increase gangrenous cholecystitis?
Not available
S-EPMC9755784
|
biostudies-literature
Cite
Awareness and preparedness of healthcare workers against the first wave of the COVID-19 pandemic: A cross-sectional survey across 57 countries.
Not available
S-EPMC8694437
|
biostudies-literature
Cite
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Not available
S-EPMC12303861
|
biostudies-literature
Cite
Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12338332
|
biostudies-literature
Cite
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535840
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets